These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 8339212)

  • 1. Combined plateletpheresis and cytotoxic chemotherapy for symptomatic thrombocytosis in myeloproliferative disorders.
    Baron BW; Mick R; Baron JM
    Cancer; 1993 Aug; 72(4):1209-18. PubMed ID: 8339212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic plateletpheresis in a case of symptomatic thrombocytosis in chronic myeloid leukemia.
    Thakral B; Saluja K; Malhotra P; Sharma RR; Marwaha N; Varma S
    Ther Apher Dial; 2004 Dec; 8(6):497-9. PubMed ID: 15663550
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of thrombocytapheresis in the contemporary management of hyperthrombocytosis in myeloproliferative neoplasms: A case-based review.
    Boddu P; Falchi L; Hosing C; Newberry K; Bose P; Verstovsek S
    Leuk Res; 2017 Jul; 58():14-22. PubMed ID: 28380402
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term plateletpheresis in the management of primary thrombocytosis.
    Goldfinger D; Thompson R; Lowe C; Kurz L; Belkin G
    Transfusion; 1979; 19(3):336-8. PubMed ID: 452073
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Primary thrombocythemia: a current perspective.
    Mughal TI
    Stem Cells; 1995 Jul; 13(4):355-9. PubMed ID: 7549894
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improvement of platelet function following plateletpheresis in patients with myeloproliferative diseases.
    Orlin JB; Berkman EM
    Transfusion; 1980; 20(5):540-5. PubMed ID: 7423594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hydroxyurea versus busulfan in the treatment of chronic myelogenous leukemia.
    Rushing D; Goldman A; Gibbs G; Howe R; Kennedy BJ
    Am J Clin Oncol; 1982 Jun; 5(3):307-13. PubMed ID: 6952759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of alpha interferon and hydroxyurea in late phase refractory myeloproliferative disease.
    Litam PP; Landaw SA; Zamkoff KW
    Haematologia (Budap); 1994; 26(2):87-90. PubMed ID: 7890266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Toxicity and side effects of hydroxyurea used for primary thrombocythemia.
    Randi ML; Ruzzon E; Tezza F; Luzzatto G; Fabris F
    Platelets; 2005; 16(3-4):181-4. PubMed ID: 16011962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Busulfan versus hydroxyurea in long-term therapy of chronic myelogenous leukemia.
    Bolin RW; Robinson WA; Sutherland J; Hamman RF
    Cancer; 1982 Nov; 50(9):1683-6. PubMed ID: 6956430
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic plateletpheresis in thombocythemia.
    Panlilio AL; Reiss RF
    Transfusion; 1979; 19(2):147-52. PubMed ID: 432925
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclical thrombocytosis, acquired von Willebrand syndrome and aggressive non-melanoma skin cancers are common in patients with Philadelphia-negative myeloproliferative neoplasms treated with hydroxyurea.
    Verner E; Forsyth C; Grigg A
    Leuk Lymphoma; 2014 May; 55(5):1139-43. PubMed ID: 23879199
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: prolongation of survival by hydroxyurea. The German CML Study Group.
    Hehlmann R; Heimpel H; Hasford J; Kolb HJ; Pralle H; Hossfeld DK; Queisser W; Löffler H; Heinze B; Georgii A
    Blood; 1993 Jul; 82(2):398-407. PubMed ID: 8329700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anagrelide: 20 years later.
    Emadi A; Spivak JL
    Expert Rev Anticancer Ther; 2009 Jan; 9(1):37-50. PubMed ID: 19105705
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of blood component removal in essential and reactive thrombocytosis.
    Greist A
    Ther Apher; 2002 Feb; 6(1):36-44. PubMed ID: 11886575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hydroxyurea in the management of the hematologic complications of chronic granulocytic leukemia.
    Schwartz JH; Cannellos GP
    Blood; 1975 Jul; 46(1):11-6. PubMed ID: 1055610
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Control of thrombocytosis by plateletpheresis using a cell separator.
    Beard ME; Blacklock HA; Varcoe AR
    N Z Med J; 1980 Feb; 91(654):136-8. PubMed ID: 6929973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Busulfan is effective second-line therapy for older patients with Philadelphia-negative myeloproliferative neoplasms intolerant of or unresponsive to hydroxyurea.
    Douglas G; Harrison C; Forsyth C; Bennett M; Stevenson W; Hounsell J; Ratnasingam S; Ritchie D; Ross DM; Grigg A
    Leuk Lymphoma; 2017 Jan; 58(1):89-95. PubMed ID: 27454522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thrombocytosis associated with a myeloproliferative disorder in a dog.
    Degen MA; Feldman BF; Turrel JM; Goding B; Kitchell B; Mandell CP
    J Am Vet Med Assoc; 1989 May; 194(10):1457-9. PubMed ID: 2722642
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anagrelide: analysis of long-term efficacy, safety and leukemogenic potential in myeloproliferative disorders.
    Fruchtman SM; Petitt RM; Gilbert HS; Fiddler G; Lyne A;
    Leuk Res; 2005 May; 29(5):481-91. PubMed ID: 15755500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.